Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005
Open Access
- 11 October 2012
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 88 (1) , 60-65
Abstract
Clinical management of lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM) has changed considerably over recent years, reflected in the use of new therapeutic agents (purine analogs, monoclonal antibodies, thalidomide‐ and bortezomib‐based therapies). No population‐based studies and few randomized trials have been performed to assess survival in newly diagnosed LPL/WM. We performed a large population‐based study in Sweden including 1,555 LPL/WM patients diagnosed from 1980 to 2005. Relative survival ratios (RSRs) and excess mortality rate ratios (EMRR) were computed as measures of survival. Survival of LPL/WM patients has improved significantly (P = 0.007) over time with 5‐year RSR = 0.57 (95% confidence interval [CI] 0.46–0.68), 0.65 (0.57–0.73), 0.74 (0.68–0.80), 0.72 (0.66–0.77), and 0.78 (0.71–0.85) for patients diagnosed during the calendar periods 1980–1985, 1986–1990, 1991–1995, 1996–2000, and 2001–2005, respectively. Improvement in 1‐ and 5‐year relative survival was found in all age groups and for LPL and WM separately. Patients with WM had lower excess mortality compared to LPL (EMRR = 0.38; 95% CI 0.30–0.48). Older age at diagnosis was associated with a poorer survival (P < 0.001). Taken together, we found a significant improvement in survival in LPL/WM over time. Despite this progress, new effective agents with a more favourable toxicity profile are needed to further improve survival in LPL/WM, especially in the elderly. Am. J. Hematol. 2013.Keywords
This publication has 38 references indexed in Scilit:
- Immune-Related and Inflammatory Conditions and Risk of Lymphoplasmacytic Lymphoma or Waldenstrom MacroglobulinemiaJNCI: Journal of the National Cancer Institute, 2010
- Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie CellulaireHaematologica, 2010
- How I treat Waldenström macroglobulinemiaBlood, 2009
- Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in SwedenHaematologica, 2009
- Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaBlood, 2009
- Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's MacroglobulinemiaJournal of Clinical Oncology, 2009
- Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in SwedenBlood, 2008
- Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003Journal of Clinical Oncology, 2007
- Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 casesBritish Journal of Haematology, 2001
- Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia — a new syndrome?Acta Medica Scandinavica, 1944